Q-omics provides the consensus-scored LRRC20 profile across patient tissues and cancer cell-line models. LRRC20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC20 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, LRRC20 protein abundance shows 20,023 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRP, and PDAC as cancer lineages where LRRC20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC20 survival associations across molecular data types. LRRC20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC20 RNA expression–survival associations across cancer types. High LRRC20 expression shows unfavorable associations in UVM, KICH and ACC, but favorable associations in KIRP, SKCM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC20 RNA expression.
This table summarizes LRRC20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC20 shows lower tumor expression in HNSC and higher tumor expression in KIRP, LUAD, COAD, KIRC and LIHC. The KIRP box plot shows higher LRRC20 RNA expression in tumor versus normal tissue (log2 FC = +1.824, t-test p < 0.001).
This table shows molecular features associated with LRRC20 in patient tissues and cancer cell lines. In patient samples, LRRC20 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
